From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement

Bispecific antibody dose schedules in relapsed/refractory multiple myeloma

Last Updated: Friday, March 29, 2024

A panel discussed available treatment options for patients with relapsed/refractory multiple myeloma, including bispecific antibody therapies. They reviewed strategies for administering these agents across various step-up doses and modifying treatment schedules following toxicity in the context of 2 patient cases.

Transplantation and Cellular Therapy

Patient-reported outcomes in long-term survivors of autologous hematopoietic cell transplantation in multiple myeloma

Journal of the Advanced Practitioner in Oncology

Patient-reported outcomes with belantamab mafodotin treatment in patients with triple-class refractory multiple myeloma

Cancer Discovery

CAR T-cell availability for multiple myeloma improving but still limited

Platelets

Multiple myeloma and its treatment contribute to increased platelet reactivity

European Journal of Haematology

Treatment sequences and drug costs from diagnosis to death in multiple myeloma

Transplantation and Cellular Therapy

Ethical challenges in CAR-T slot allocations

Nature

Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders

Clinical Journal of Oncology Nursing

Steroid-associated side effects: A symptom management update on multiple myeloma treatment

The Lancet

SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis

Blood

Final results from the first-in-human phase 1/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)

A Heavily Treated Relapsed/Refractory Multiple Myeloma Patient on Talquetamab

First Relapse of Multiple Myeloma Patient

Treatment of Relapsed Multiple Myeloma With Bispecific Antibodies